Impact of interleukin 6 -174G>C polymorphism on obesity-related metabolic disorders in people with excess in body weight.

[1]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[2]  T. Hedner,et al.  A common polymorphism in the interleukin-6 gene promoter is associated with overweight , 2004, International Journal of Obesity.

[3]  J. Martínez,et al.  Body-weight regulation: causes of obesity , 2000, Proceedings of the Nutrition Society.

[4]  C. Fox,et al.  BMI Modifies Associations of IL‐6 Genotypes with Insulin Resistance: The Framingham Study , 2006, Obesity.

[5]  M. Laakso,et al.  Effect of the interleukin-6 (-174) g/c promoter polymorphism on adiponectin and insulin sensitivity. , 2005, Obesity research.

[6]  J. Martínez,et al.  Postprandial insulin response and mitochondrial oxidation in obese men nutritionally treated to lose weight , 2005, European Journal of Clinical Nutrition.

[7]  C. Gieger,et al.  IL6 Gene Promoter Polymorphisms and Type 2 Diabetes , 2006, Diabetes.

[8]  I. Vauhkonen,et al.  The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. , 2003, Diabetes.

[9]  M. D. Parra,et al.  Implicación de la IL-6 y su polimorfismo -174G>C en el control del peso corporal y en las complicaciones metabólicas asociadas a la obesidad , 2005 .

[10]  H. Boeing,et al.  Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  J. Després,et al.  The interleukin 6 –174G/C Polymorphism is associated with indices of obesity in men , 2003, Journal of Human Genetics.

[12]  S. Humphries,et al.  A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus. , 2004, Molecular genetics and metabolism.

[13]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[14]  D. Panagiotakos,et al.  The IL-6 gene G-174C polymorphism related to health indices in Greek primary school children. , 2004, Obesity research.

[15]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[16]  J. Powell,et al.  Interleukin-6 (IL-6) and the Prognosis of Abdominal Aortic Aneurysms , 2001, Circulation.

[17]  J. Fernández-Real.  Genetic predispositions to low-grade inflammation and type 2 diabetes. , 2006, Diabetes technology & therapeutics.

[18]  M. Margaglione,et al.  Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. , 2004, Metabolism: clinical and experimental.

[19]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[20]  A. Goldberg,et al.  Interleukin-6 genotype is associated with high-density lipoprotein cholesterol responses to exercise training. , 2005, Biochimica et biophysica acta.

[21]  E. Hawe,et al.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. , 2001, European heart journal.

[22]  M. D. Parra,et al.  Impact of weight loss on cortisol secretion in obese men with and without metabolic syndrome features. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[23]  R. Hanson,et al.  The interleukin-6 (−174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians , 2003, Human Genetics.

[24]  J. Manson,et al.  Mediating effects of inflammatory biomarkers on insulin resistance associated with obesity. , 2005, Obesity research.

[25]  A. Pasternack,et al.  Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease. , 2001, Rheumatology.

[26]  E. Ravussin,et al.  Metabolic differences and the development of obesity. , 1995, Metabolism: clinical and experimental.

[27]  E. Bruckert,et al.  Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. , 2002, The Journal of clinical endocrinology and metabolism.

[28]  V. Mohan,et al.  Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance--the Chennai Urban Rural Epidemiology Study (CURES). , 2006, Metabolism: clinical and experimental.

[29]  A. Greenberg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Omental and Subcutaneous Adipose Tissues of Obese Subjects Release Interleukin-6: Depot Difference and Regulation by Glucocorticoid* , 1997 .

[30]  C Bogardus,et al.  Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. , 2001, Obesity research.

[31]  K. Kagawa,et al.  Angiotensinogen gene polymorphism (Met235Thr) influences visceral obesity and insulin resistance in obese Japanese women. , 2006, Metabolism: clinical and experimental.

[32]  J. Manson,et al.  Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. , 2006, Human molecular genetics.

[33]  J. Lachin.  Operating characteristics of sample size re‐estimation with futility stopping based on conditional power , 2006, Statistics in medicine.

[34]  R. Holle,et al.  Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[35]  J. Martínez,et al.  Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome-proliferator-activated-receptor-γ2 gene polymorphisms , 2006, British Journal of Nutrition.

[36]  F. Pi‐Sunyer,et al.  Pathophysiology and long-term management of the metabolic syndrome. , 2004, Obesity research.

[37]  D. Papanicolaou,et al.  Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  W. Shoemaker,et al.  The effect of obesity on bioimpedance cardiac index. , 2005, American journal of surgery.

[39]  J. Pickup,et al.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X , 1997, Diabetologia.

[40]  J. Fernández-Real,et al.  Insulin resistance and chronic cardiovascular inflammatory syndrome. , 2003, Endocrine reviews.

[41]  J. Sundell.  Obesity and diabetes as risk factors for coronary artery disease: from the epidemiological aspect to the initial vascular mechanisms , 2005, Diabetes, obesity & metabolism.

[42]  T. Hansen,et al.  Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes , 2005, Diabetologia.

[43]  R. Talamini,et al.  Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease , 2006, Journal of Clinical Pathology.

[44]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.